Tasca Therapeutics launches with $52 million Series A financing

Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group.

This funding will be used to advance Tasca’s novel drug discovery platform, progress its lead program, CP-383, into Phase I/II clinical proof-of-concept studies, and to expand its drug candidate pipeline.

“We are excited to enter this next phase of company growth with financial support from such leading life science investors and the continued backing of our pioneering scientific co-founders - Xu Wu, Dr David Fisher and Duojia Pan,” said Milenko Cicmil, co-founder and chief executive of Tasca. “Our first development candidate, CP-383, is a unique first-in-class molecule demonstrating excellent efficacy across multiple cancer types and we are looking forward to progressing it into the clinic,” he noted.